XBiotech Inc. (XBIT)

$3.69

-0.02 (-0.54%)
Rating:
Recommendation:
Neutral
Symbol XBIT
Price $3.69
Beta 1.288
Volume Avg. 0.05M
Market Cap 112.321M
Shares () -
52 Week Range 3.53-16.47
1y Target Est -
DCF Unlevered XBIT DCF ->
DCF Levered XBIT LDCF ->
ROE -10.05% Sell
ROA -10.05% Sell
Operating Margin -
Debt / Equity 4.17% Neutral
P/E -
P/B 0.44 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest XBIT news


Mr. John Simard
Healthcare
Biotechnology
NASDAQ Global Select

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.